A new oncolytic virus therapy that is intended to treat solid tumours is poised to enter clinical development triggering a $15 million milestone payment from Bristol-Myers Squibb Co to the developer PsiOxus Therapeutics Ltd of Oxford, UK.
NorthSea Therapeutics BV, a Dutch company established in November 2017 to exploit a licence for a NASH treatment called icosabutate, has raised €25 million in a Series A equity financing that will allow the company to run a critical Phase 2b, proof-of-concept study of the drug by the end of 2018.
Netherlands-based LSP (Life Sciences Partners) has raised €280 million in the first and final closing of a new medical technology fund that will invest in companies developing medical devices, diagnostics and applications for digital health.
The US Food and Drug Administration has approved a follow-on, or biosimilar, medicine for diabetes from Sanofi SA that is intended to improve the control of blood sugar in children and adults with both Type 1 and Type 2 forms of the disease.
Hookipa Biotech AG has raised €50 million in an oversubscribed Series C financing to support the clinical development of vaccines for infectious diseases and cancer. The round was led by an undisclosed US public investment fund.
Belgium-based Aelin Therapeutics has received €27 million in Series A financing from a syndicate of investors to develop a new class of antibiotics against human targets that thus far have been undruggable. The company is a spin-out of the VIB research institute.
OSE Immunotherapeutics SA is set to resume recruitment into a Phase 3 trial of patients with non-small cell lung cancer (NSCLC) following a pause in June to enable investigators to have more time to assess the effect of the treatment which is a neoantigen therapy called Tedopi.
The French specialist pharma company Advicenne Pharma SA raised €27 million in an initial public offering (IPO) of its shares on the Paris Euronext exchange on 4 December to advance its pipeline of drugs for orphan renal and neurological diseases.
Medigene has raised its revenue forecast for 2017 following an agreement to sell its product for the treatment of genital wards, Veregen, to a subsidiary of Novartis. The sale finishes the disposal of its legacy products, enabling the company to focus on immunotherapy.
GW Pharmaceuticals Plc said it intends to issue $225 million worth of its shares on the US Nasdaq market subject to market conditions and investor appetite.